SCHEMBL23958684

SCHEMBL23958684

CC(C)(C)OC(=O)NCC(C)(O)c1cc(C(C)(C)O)c(Cl)c(-c2ccc(F)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CFTR P13569 3/20 0.41
GRM2 Q14416 1/20 0.40
BRD4 O60885 2/20 0.36
LATS1 O95835 2/20 0.35
TRPV1 Q8NER1 1/20 0.34
CNR1 P21554 2/20 0.34
CNR2 P34972 2/20 0.34
LATS2 Q9NRM7 1/20 0.34
AAK1 Q2M2I8 1/20 0.34
GNRHR P30968 1/20 0.34
SCN9A Q15858 2/20 0.33
CKS1B P61024 1/20 0.33
SKP1 P63208 1/20 0.33
SKP2 Q13309 1/20 0.33
FPR2 P25090 1/20 0.33
MAPT P10636 1/20 0.33
CTSS P25774 1/20 0.33
CTSK P43235 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25686536 0.90 CFTR (0.42) CFTRGRM2BRD4LATS1TRPV1
SCHEMBL23958912 0.89 CFTR (0.42) CFTRGRM2BRD4LATS1
SCHEMBL28909204 0.88 CFTR (0.41) CFTR
SCHEMBL25686935 0.87 CFTR (0.38) CFTRGRM2LATS1CKS1BSKP1
SCHEMBL30007222 0.87 CFTR (0.38) CFTRGRM2LATS1CKS1BSKP1
SCHEMBL23958820 0.81 CFTR (0.37) CFTRCNR1CNR2SCN9AFPR2
SCHEMBL23958697 0.81 CFTR (0.44) CFTRGRM2BRD4LATS1LATS2
SCHEMBL25686912 0.79 CFTR (0.41) CFTRGRM2BRD4LATS1TRPV1
SCHEMBL23958691 0.79 CFTR (0.38) CFTRGRM2TRPV1AAK1GNRHR
SCHEMBL25279639 0.79 CFTR (0.43) CFTRCNR1CNR2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
WO-2021214136-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES Janssen Sciences Ireland Unlimited Company (IE) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203004-A1 RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES ACE2, SIRT7, ACE CFTR 508/4885GRM2 3975/4885BRD4 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.